1. Safety, Pharmacokinetics, and Pharmacodynamics of Etavopivat (FT‐4202), an Allosteric Activator of Pyruvate Kinase‐R, in Healthy Adults: A Randomized, Placebo‐Controlled, Double‐Blind, First‐in‐Human Phase 1 Trial. Issue 5 (12th January 2022) Authors: Forsyth, Sanjeev; Schroeder, Patricia; Geib, James; Vrishabhendra, Leela; Konstantinidis, Diamantis G.; LaSalvia, Kari; Ribadeneira, Maria D.; Wu, Eric; Kelly, Patrick; Kalfa, Theodosia A. Journal: Clinical pharmacology in drug development Issue: Volume 11:Issue 5(2022) Page Start: 654 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗